Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT02791269
Registration number
NCT02791269
Ethics application status
Date submitted
31/05/2016
Date registered
6/06/2016
Date last updated
6/02/2017
Titles & IDs
Public title
A Study of Peginterferon Alfa-2a in Participants With Chronic Hepatitis B Virus (HBV) in an Expanded Access Program
Query!
Scientific title
Expanded Access Program of PEGASYS® (Peg Interferon Alpha-2a 40 KD) in Patients With HBeAg-Positive And HBeAg-Negative Chronic Hepatitis B
Query!
Secondary ID [1]
0
0
ML19295
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Hepatitis B, Chronic
0
0
Query!
Condition category
Condition code
Infection
0
0
0
0
Query!
Other infectious diseases
Query!
Oral and Gastrointestinal
0
0
0
0
Query!
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Peginterferon alfa-2a
Experimental: HBeAg Negative Participants - HBeAg negative participants will receive peginterferon alfa-2a 180 micrograms (mcg) subcutaneous (SC) injection once weekly (QW) for 48 weeks followed by a 24 weeks treatment-free follow-up period.
Experimental: HBeAg Positive Participants - HBeAg Positive participants will receive peginterferon alfa-2a 180 mcg SC injection QW for 48 weeks followed by a 24 weeks treatment-free follow-up period.
Treatment: Drugs: Peginterferon alfa-2a
180 mcg SC injection QW for 48 weeks.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Number of HBeAg Positive Participants With Hepatitis B Virus-deoxy Ribonucleic Acid (HBV-DNA) Less Than (<) 100,000 Copies Per Milliliter (Copies/mL)
Query!
Assessment method [1]
0
0
HBV-DNA was assessed in plasma samples using quantitative Roche polymerase chain reaction (PCR) or Taqman tests.
Query!
Timepoint [1]
0
0
End of 24-weeks follow-up (Week 72)
Query!
Primary outcome [2]
0
0
Number of Participants With HBV-DNA <20,000 Copies/mL
Query!
Assessment method [2]
0
0
HBV-DNA was assessed in plasma samples using quantitative Roche PCR or Taqman tests.
Query!
Timepoint [2]
0
0
End of 24-weeks follow-up (Week 72)
Query!
Secondary outcome [1]
0
0
Number of Participants With HBV-DNA <400 Copies/mL
Query!
Assessment method [1]
0
0
HBV-DNA was assessed in plasma samples using quantitative Roche PCR or Taqman tests.
Query!
Timepoint [1]
0
0
Week 48 (end of treatment) and Week 72 (end of follow-up)
Query!
Secondary outcome [2]
0
0
Number of Participants With Hepatitis B Surface Antigen (HBsAg) Seroconversion
Query!
Assessment method [2]
0
0
HBsAg seroconversion was defined as the absence of HBsAg (a negative result for HBsAg) and the presence of anti-HBs (a positive result for anti-HBs). Both HBeAg positive and negative participants were HBsAg positive at baseline and absence of HBsAg (seroconversion) was analyzed.
Query!
Timepoint [2]
0
0
Week 48 (end of treatment) and Week 72 (end of follow-up)
Query!
Secondary outcome [3]
0
0
Number of Participants With Normalization of Alanine Aminotransferase (ALT) Level
Query!
Assessment method [3]
0
0
ALT is an enzyme found mainly in liver and is measured to check if the liver is damaged or diseased. In case of liver damage or disease, the liver releases ALT into the blood stream and the ALT level increases. Normal ALT level = less than upper limit of normal (40 units per liter).
Query!
Timepoint [3]
0
0
Week 48 (end of treatment) and Week 72 (end of follow-up)
Query!
Secondary outcome [4]
0
0
Number of Participants With HBeAg Seroconversion
Query!
Assessment method [4]
0
0
HBeAg seroconversion for HBeAg positive participants was defined as the loss of HBeAg (a negative result for HBeAg) and the presence of anti-HBe (a positive result for anti-HBe).
Query!
Timepoint [4]
0
0
Week 48 (end of treatment) and Week 72 (end of follow-up)
Query!
Eligibility
Key inclusion criteria
- Non-cirrhotic participants
- Hepatitis B surface antigen (HBsAg) positive for at least 6 months
- Hepatitis B surface antibody (anti-HBs) negative
- Elevated serum alanine aminotransferase (ALT) greater than (>) upper limit of normal
(ULN) but less than or equal to (</=) 10 times of ULN
- HBeAg positive participants: HBV DNA > 500,000 copies/mL, HBeAg negative participants:
HBV DNA >100,000 copies/mL by polymerase chain reaction (PCR)
- Participants with chronic hepatitis B (CHB) who are treatment-naive
- No previous antiviral treatment with interferon (IFN: standard or pegylated) or with a
nucleoside analogue
- For women of childbearing potential: negative urine or serum pregnancy test documented
within the 24-hour period prior to the first dose of test drug. Willingness to use
reliable contraception during the study and for 3 months after treatment completion
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
70
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Previous antiviral or IFN-based therapy for CHB before enrolment
- Pregnant or breast feeding women participants
- Evidence of decompensated liver disease
- Co-infection with active hepatitis A, hepatitis C, hepatitis D and/or human
immunodeficiency virus (HIV)
- History or other evidence of a medical condition associated with chronic liver disease
other than viral hepatitis
- Previous or current hepatocellular carcinoma
- History of or other evidence of bleeding from esophageal varices or other conditions
consistent with decompensated liver disease
- Alpha-fetoprotein levels of >100 nanograms (ng)/mL
- Severe psychiatric disease
- History of a severe seizure disorder or current anticonvulsant use
- History of immunologically mediated disease, chronic pulmonary disease associated with
functional limitation, severe cardiac disease, major organ transplantation or other
evidence of severe illness, malignancy, or any other conditions which would make the
participant, in the opinion of the investigator, unsuitable for the study
- Thyroid disease uncontrolled by prescribed medications
- Evidence of severe retinopathy
- Alcohol intake more than 3 standard drinks per day for men and 2 standard drinks per
day for women
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 4
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/01/2006
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/07/2008
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
24
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment outside Australia
Country [1]
0
0
New Zealand
Query!
State/province [1]
0
0
Auckland
Query!
Country [2]
0
0
New Zealand
Query!
State/province [2]
0
0
Hamilton
Query!
Country [3]
0
0
New Zealand
Query!
State/province [3]
0
0
New Plymouth
Query!
Country [4]
0
0
New Zealand
Query!
State/province [4]
0
0
Riccarton, Christchurch
Query!
Country [5]
0
0
New Zealand
Query!
State/province [5]
0
0
Rotorua
Query!
Country [6]
0
0
New Zealand
Query!
State/province [6]
0
0
Whangarei
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Hoffmann-La Roche
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This is an expanded access, multicenter, national, open-label, and non-randomized study to
analyze the safety of peginterferon alfa-2a in participants with hepatitis B e antigen
(HBeAg) positive and HBeAg negative chronic HBV infection. All participants will receive 48
weeks treatment of peginterferon alfa-2a monotherapy, followed by a 24 week treatment-free
follow-up period.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT02791269
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Clinical Trials
Query!
Address
0
0
Hoffmann-La Roche
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT02791269
Download to PDF